609 related articles for article (PubMed ID: 18847312)
1. Yellow fever vaccine: past, present and future.
Roukens AH; Visser LG
Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
4. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
5. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
6. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
[TBL] [Abstract][Full Text] [Related]
7. Yellow fever vaccines and international travelers.
Barnett ED; Wilder-Smith A; Wilson ME
Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
[TBL] [Abstract][Full Text] [Related]
8. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
Baba MM; Ikusemoran M
Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
Wieten RW; Jonker EF; Pieren DK; Hodiamont CJ; van Thiel PP; van Gorp EC; de Visser AW; Grobusch MP; Visser LG; Goorhuis A
Vaccine; 2016 Mar; 34(10):1247-51. PubMed ID: 26845742
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of the 17D-204 yellow fever vaccine.
Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
[TBL] [Abstract][Full Text] [Related]
11. A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.
Calvert AE; Dixon KL; Piper J; Bennett SL; Thibodeaux BA; Barrett AD; Roehrig JT; Blair CD
Antiviral Res; 2016 Jul; 131():92-9. PubMed ID: 27126613
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
13. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
Roukens AH; Soonawala D; Joosten SA; de Visser AW; Jiang X; Dirksen K; de Gruijter M; van Dissel JT; Bredenbeek PJ; Visser LG
PLoS One; 2011; 6(12):e27753. PubMed ID: 22163273
[TBL] [Abstract][Full Text] [Related]
14. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
[TBL] [Abstract][Full Text] [Related]
15. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
16. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
Roukens AH; Vossen AC; Bredenbeek PJ; van Dissel JT; Visser LG
PLoS One; 2008 Apr; 3(4):e1993. PubMed ID: 18431480
[TBL] [Abstract][Full Text] [Related]
17. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
[TBL] [Abstract][Full Text] [Related]
18. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
[TBL] [Abstract][Full Text] [Related]
19. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
20. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
Barrett ADT
Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
